ADMA Biologics Files 8-K Report

Ticker: ADMA · Form: 8-K · Filed: May 17, 2024 · CIK: 1368514

Adma Biologics, Inc. 8-K Filing Summary
FieldDetail
CompanyAdma Biologics, Inc. (ADMA)
Form Type8-K
Filed DateMay 17, 2024
Risk Levellow
Pages2
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, sec-filing

TL;DR

ADMA Biologics filed a routine 8-K, no major news yet.

AI Summary

On May 17, 2024, ADMA Biologics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt, but it indicates a standard regulatory filing.

Why It Matters

This filing indicates ADMA Biologics is meeting its regulatory disclosure requirements with the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for regulatory disclosure and does not appear to contain any new material information or negative developments.

Key Players & Entities

  • ADMA BIOLOGICS, INC. (company) — Registrant
  • May 17, 2024 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 001-36728 (filing_id) — SEC File Number
  • 56-2590442 (tax_id) — IRS Employer Identification No.
  • Ramsey, New Jersey (location) — Principal executive offices
  • R&R ACQUISITION VI, INC (company) — Former company name

FAQ

What is the primary purpose of this 8-K filing for ADMA Biologics?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits, as indicated by the filing details.

On what date was this 8-K report filed?

This 8-K report was filed on May 17, 2024.

In which U.S. state is ADMA Biologics, Inc. incorporated?

ADMA Biologics, Inc. is incorporated in Delaware.

What is the SEC file number for ADMA Biologics?

The SEC file number for ADMA Biologics is 001-36728.

What was ADMA Biologics, Inc.'s former company name?

ADMA Biologics, Inc.'s former company name was R&R ACQUISITION VI, INC.

Filing Stats: 719 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2024-05-17 09:00:26

Filing Documents

01

Item 7.01 Regulation FD. ADMA Biologics, Inc., a Delaware corporation (the "Company"), hereby furnishes the Corporate Presentation the Company expects to present, in whole or in part, and possibly with modifications, from time to time in connection with presentations to potential investors, strategic partners, industry analysts and others. The Corporate Presentation is attached hereto as Exhibit 99.1 and is incorporated by reference herein, and is available under the "Corporate Presentation" tab in the "Investors" section of the Company's website, located at www. admabiologics.com. By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information contained in the Corporate Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, except as may be required by the federal securities laws, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. The information furnished pursuant to this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be considered "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless t

01

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 ADMA Biologics, Inc. May 2024 Corporate Presentation. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. May 17, 2024 ADMA Biologics, Inc. By: /s/ Adam S. Grossman Name: Adam S. Grossman Title: President, Chief Executive Officer and Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.